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Abstract
Gestational	trophoblastic	disease	(GTD)	arises	from	abnormal	placenta	and	is	composed	
of	a	spectrum	of	premalignant	to	malignant	disorders.	Changes	in	epidemiology	of	GTD	
have	 been	 noted	 in	 various	 countries.	 In	 addition	 to	 histology,	 molecular	 genetic	
studies	can	help	 in	the	diagnostic	pathway.	Earlier	detection	of	molar	pregnancy	by	
ultrasound	has	 resulted	 in	 changes	 in	 clinical	presentation	and	decreased	morbidity	
from	 uterine	 evacuation.	 Follow-	up	 with	 human	 chorionic	 gonadotropin	 (hCG)	 is	
essential	for	early	diagnosis	of	gestational	trophoblastic	neoplasia	(GTN).	The	duration	
of	hCG	monitoring	varies	depending	on	histology	type	and	regression	rate.	Low-	risk	
GTN	(FIGO	Stages	I–III:	score	<7)	is	treated	with	single-	agent	chemotherapy	but	may	
require	 additional	 agents;	 although	 scores	 5–6	 are	 associated	 with	 more	 drug	
resistance,	overall	survival	approaches	100%.	High-	risk	GTN	(FIGO	Stages	II–III:	score	
>7	and	Stage	IV)	is	treated	with	multiple	agent	chemotherapy,	with	or	without	adjuvant	
surgery	for	excision	of	resistant	foci	of	disease	or	radiotherapy	for	brain	metastases,	
achieving	a	survival	rate	of	approximately	90%.	Gentle	induction	chemotherapy	helps	
reduce	early	deaths	 in	patients	with	extensive	 tumor	burden,	but	 late	mortality	still	
occurs	from	recurrent	resistant	tumors.
K E Y W O R D S
Choriocarcinoma;	Epithelioid	trophoblastic	tumor;	FIGO	Cancer	Report;	Gestational	trophoblastic	
neoplasia;	Moles;	Placental	site	trophoblastic	tumor
1  | INTRODUCTION
Gestational	 trophoblastic	 disease	 (GTD)	 is	 a	 group	 of	 uncommon	
conditions	 associated	with	pregnancy.	Histologically,	 it	 includes	 the	
premalignant	partial	 (PHM)	and	complete	hydatidiform	mole	(CHM),	
as	 well	 as	 the	 malignant	 invasive	 mole,	 choriocarcinoma,	 placental	
site	 trophoblastic	 tumor	 (PSTT),	and	epithelioid	 trophoblastic	 tumor	
(ETT).	The	malignant	forms	can	arise	after	any	type	of	pregnancy	and	
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are	collectively	known	as	gestational	 trophoblastic	neoplasia	 (GTN).	
The	GTD	spectrum	has	recently	been	expanded	to	also	include	atypi-
cal	 placental	 site	 nodule	 (APSN)	 as	 10%–15%	may	 coexist	 with	 or	
develop	 into	 PSTT/ETT.1	 While	 PSTT,	 ETT,	 and	 APSN	 have	 more	
varied	production	of	the	pregnancy	hormone—human	chorionic	gon-
adotropin	(hCG)—all	other	forms	of	GTD	produce	this	hormone	very	
well.	 Indeed,	 hCG	 is	 an	 excellent	 biomarker	 of	 disease	progression,	
response,	 and	 subsequent	 post-	treatment	 surveillance.	 Thus,	 a	 pla-
teaued	or	rising	hCG	level	enables	the	early	detection	of	progression	
of	CHM	and	PHM	to	GTN	 that	occurs	 in	15%–20%,	 and	0.5%–5%	
of	cases,	respectively.2,3	The	use	of	this	biomarker	together	with	the	
development	 of	 highly	 effective	 therapies	 has	 transformed	 survival	
outcomes	so	that	today	nearly	all	women	affected	by	GTN	can	expect	
to	be	cured	if	managed	properly.
2  | EPIDEMIOLOGY
Although	epidemiological	studies	have	reported	a	wide	variation	in	the	
incidence	of	hydatidiform	mole,	in	most	parts	of	the	world	it	is	1	per	
1000 pregnancies.4	 In	high-	income	countries,	the	 incidence	of	com-
plete	mole	is	approximately	1–3	per	1000	pregnancies	and	the	inci-
dence	of	partial	mole	is	about	3	per	1000	pregnancies.3	Hydatidiform	
mole	appears	to	be	caused	by	abnormal	gametogenesis	and	fertiliza-
tion,5,6	more	frequent	at	the	extremes	of	reproductive	age	(<15	and	
>45	years)	and	pregnancies	at	these	ages	are	a	risk	factor	for	hydatidi-
form	mole.	The	risk	increases	after	age	35	and	there	is	a	5–10	times	
increased	risk	after	45	years.	Teenagers	have	a	two-	fold	risk	of	hav-
ing	a	molar	pregnancy.	There	is	an	increasing	risk	for	complete	moles	
with	advancing	maternal	age.7	History	of	a	previous	molar	pregnancy	
increases	the	risk	to	10	times	that	for	sporadic	moles.
The	 reported	 incidence	 of	 choriocarcinoma	 ranges	 from	 1	 in	
40	000	 pregnancies	 in	 North	 America	 and	 Europe,	 to	 9.2	 and	 3.3	
per	 40	000	 pregnancies	 in	 Southeast	Asia	 and	 Japan,	 respectively.2 
Dietary	deficiency	of	beta-	carotene	and	animal	fat	is	considered	to	be	
etiological	factor	for	complete	mole,	but	not	for	partial	mole.8
3  | GENETICS AND PATHOLOGY
3.1 | Molar pregnancy
Grossly,	CHM	consists	of	hydropic	villi	to	semi-	transparent	vesicles	of	
variable	sizes	with	absence	of	normal	placenta.	Early	complete	hyda-
tidiform	moles	have	minimal	or	no	gross	evidence	of	abnormal	villi.
Differential	diagnoses	include	partial	hydatidiform	mole,	hydropic	
abortion,	and	early	nonmolar	gestation	with	some	degree	of	tropho-
blastic	 hyperplasia.	 Histologically,	 complete	 mole	 has	 florid	 cistern	
formation,	 trophoblastic	 proliferation,	 and	 absence	 of	 fetal	 parts.	
Significant	cytological	atypia	and	mitotic	figures	are	common.	 In	the	
first	trimester,	CMH	villi	may	not	be	enlarged	but	have	a	distinct	pol-
ypoid	 appearance	 with	 abnormal	 villous	 stromal	 changes	 and	 mild	
to	 moderate	 trophoblastic	 hyperplasia.	 In	 contrast,	 such	 histologic	
features	 are	 less	marked	 in	 partial	mole	 and	 fetal	 parts	 or	 cells	 are	
present.3	Hydropic	spontaneous	abortion	may	mimic	the	appearance	
of	partial	mole.
A	cyclin-	dependent	kinase	inhibitor	p57	is	encoded	by	the	pater-
nally	imprinted	and	maternally	expressed	gene	and	hence	is	absent	in	
CHM	without	the	maternal	genome.	In	contrast,	PHM	and	nonmolar	
abnormal	gestations	with	maternal	genome	have	strong	nuclear	p57	
staining,	which	can	be	used	to	exclude	complete	mole.	However,	p57	
cannot	differentiate	PHM	from	nonmolar	gestations.	Cytogenetics	can	
help	to	differentiate	CHM	from	PHM	and	hydropic	spontaneous	abor-
tion.	Typically,	CHM	is	diploid	and	has	46,XX	chromosomes	with	both	
X’s	 from	paternal	origin,	whereas	PHM	is	triploid	with	maternal	and	
paternal	genetic	origin.	Hydropic	spontaneous	abortion	normally	has	
46,XX	or	XY	from	both	parents.3
Rarely,	invasive	and	metastatic	moles	can	be	diagnosed	by	removal	
of	the	uterus	or	biopsy	of	a	metastatic	lesion.
3.2 | Choriocarcinoma
Grossly,	the	tumor	is	bulky	with	hemorrhagic	and	necrotic	areas.	Apart	
from	the	uterus,	it	can	be	found	in	tubes,	ovaries,	lung,	liver,	spleen,	
kidneys,	bowel,	or	brain.3
Histologically,	 choriocarcinoma	 shows	 absence	 of	 chorionic	 villi	
and	presence	of	abnormal	intermediate	trophoblast	and	cytotropho-
blast,	 rimmed	with	 syncytiotrophoblasts	with	 areas	of	 necrosis,	 and	
hemorrhage.	Highly	complex	karyotypes	have	been	reported	and	an	
XX	sex	chromosome	composition	is	seen	in	the	majority.
3.3 | Placental site trophoblastic tumor
Grossly,	PSTT	appears	as	white-	tan	to	yellow	nodular	masses	varying	
from	1–10	cm	(average	5	cm)	in	the	endomyometrium	with	half	of	the	
cases	 invading	deep	 into	the	myometrium.	Histologically,	PSTT	arises	
from	the	mononuclear	 intermediate	 trophoblast	on	 the	maternal	 side	
of	 the	 placental	 bed.	 Tumor	 cells	 have	 irregular	 nuclear	membranes,	
hyperchromatic	 nuclei,	 and	 dense	 eosinophilic	 to	 amphophilic	 cyto-
plasm.	Most	tumors	have	a	low	mitotic	count.	Chorionic	villi	are	absent.	
Tumor	cells	diffusely	express	human	placental	lactogen	(hPL),	MUC-	4,	
HSD3B1,	HLA-	G,	and	Mel-	CAM	(CD146).	Expression	of	hCG	and	inhi-
bin	is	focal.	The	proliferation	index	is	generally	modestly	increased,	with	
Ki-	67	expressed	in	10%	to	30%	of	cells—higher	than	that	of	benign	exag-
gerated	placental	site	reaction.3	PSTT	shows	rare	genetic	imbalances.
3.4 | Epithelioid trophoblastic tumor
Grossly,	 the	 tumor	appears	 as	white-	tan	 to	brown	discrete	nodules	
or	cystic	hemorrhagic	masses	invading	deep	into	surrounding	tissues.	
Nearly	 half	 arise	 in	 the	 cervix	 or	 lower	 segment	 of	 the	 uterus	 and	
some	in	the	fundus	and	broad	ligament.
Histologically,	 ETT	 arises	 from	 the	 chorionic-	type	 intermediate	
trophoblast.	 Islands	 of	 relatively	 uniform	 intermediate	 trophoblastic	
cells	with	moderate	 amount	 of	 eosinophilic	 to	 clear	 cytoplasm	 and	
round	nuclei	are	surrounded	by	extensive	necrosis	and	associated	with	
a	hyaline-	like	matrix.	The	mitotic	count	ranges	from	0–9	per	10	HPF.	
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Extensive	or	“geographic”	necrosis	is	often	present.	ETT	may	coexist	
with	other	trophoblastic	neoplasms.
4  | CLINICAL PRESENTATION, 
INVESTIGATIONS, AND DIAGNOSIS
4.1 | Molar pregnancy
Patients	usually	present	with	second	trimester	vaginal	bleeding	and	a	
uterus	greater	than	the	gravid	date.	As	diagnosis	is	often	made	in	the	first	
trimester	with	ultrasound	examination,	complications	such	as	hyperem-
esis	gravidarum,	pre-	eclampsia,	and	hyperthyroidism	are	less	common.	If	
there	is	vaginal	passage	of	the	gestational	product,	vesicles	may	be	seen.
The	typical	honeycomb	appearance	of	a	complete	mole	 is	 rarely	
seen,	especially	in	the	first	trimester.	Typically,	there	is	absence	of	fetal	
parts,	cystic	appearance	of	the	placenta,	and	a	deformed	gestational	
sac	that	may	appear	like	a	spontaneous	abortion.	Hence,	some	molar	
pregnancies	are	only	diagnosed	on	histologic	examination	after	evacu-
ation	for	a	spontaneous	abortion.
4.2 | Gestational trophoblastic neoplasia
Postmolar	 GTN	 is	 usually	 diagnosed	 by	 hCG	 surveillance	 without	
symptoms.	At	the	FIGO	Gynecology	Oncology	Committee	meeting	in	
2000,	the	definition	of	postmolar	GTN	based	on	hCG-	level	changes,	
histology,	and	specific	investigations	was	agreed	(Boxes	1	and	2).9
4.3 | Human chorionic gonadotropin monitoring
For	monitoring	of	GTN,	an	hCG	assay	that	can	detect	all	forms	of	hCG	
including	beta-	hCG,	core	hCG,	C-	terminal	hCG,	nicked-	free	beta,	beta	
core,	 and	preferably	 the	hyperglycosylated	 forms,	 should	be	used.	A	
persistently	low	hCG	level	needs	continuous	monitoring	as	some	may	
progress	to	GTN	with	rising	hCG	levels.10,11	To	exclude	a	false-	positive	
result,	retest	with	another	assay	kit	or	a	test	for	urine	hCG	may	be	used.
4.4 | Gestational trophoblastic neoplasia 
after nonmolar pregnancy
As	only	about	50%	of	GTN	follows	molar	pregnancy,	 the	rest	can	
occur	 after	 a	 spontaneous	 abortion,	 ectopic	pregnancy,	 or	 a	 term	
pregnancy.	 Aside	 from	 abnormal	 vaginal	 bleeding,	 other	 clinical	
presentations	 can	 include	 bleeding	 from	metastatic	 sites	 such	 as	
the	 liver,	 spleen,	 intestines,	 lung,	 or	 brain;	 pulmonary	 symptoms;	
and	neurological	signs	from	spine	or	brain	metastasis.2	GTN	should	
be	considered	in	the	differential	diagnosis	of	patients	with	unusual	
presentations	and	serum	hCG	should	be	performed	as	part	of	 the	
workup	of	such	patients.
5  | TREATMENT
5.1 | Molar pregnancy
Suction	 evacuation	 and	 curettage,	 ideally	 performed	 under	 ultra-
sound	guidance,	 is	 the	preferred	method	of	evacuation	of	a	molar	
pregnancy	independent	of	uterine	size	if	maintenance	of	fertility	is	
desired.	It	is	recommended	that	a	12–14	mm	suction	cannula	is	used	
and	that	an	intravenous	oxytocin	infusion	is	started	at	the	onset	of	
suction	curettage	and	continued	for	several	hours	postoperatively	to	
enhance	uterine	contractility.	Because	the	risk	of	bleeding	increases	
with	 uterine	 size,	 blood	 for	 transfusion	 should	 be	 available	 when	
the	uterus	is	greater	than	16	weeks	in	gestational	size.	Rh	immune	
globulin	should	be	given	to	Rh-	negative	women	at	the	time	of	molar	
evacuation	as	RhD	factor	is	expressed	on	the	trophoblast.	Judicious	
use	 of	 appropriate	 evacuation	 equipment	 and	 techniques,	 access	
to	blood	products,	careful	intraoperative	monitoring,	and	early	rec-
ognition	 and	 correction	 of	 complications	 results	 in	 improved	 out-
comes.2,12	If	there	is	no	persistent	bleeding,	a	second	evacuation	is	
usually	not	needed.
Hysterectomy	is	an	alternative	to	suction	curettage	if	childbearing	
is	 complete.	 In	 addition	 to	 evacuating	 the	molar	 pregnancy,	 hyster-
ectomy	provides	permanent	sterilization	and	decreases	the	need	for	
subsequent	chemotherapy	by	eliminating	the	risk	of	local	myometrial	
invasion	as	a	cause	of	persistent	disease.	Medical	 induction	of	 labor	
and	 hysterotomy	 are	 not	 recommended	 for	molar	 evacuation,	 since	
these	methods	 increase	maternal	morbidity	and	the	development	of	
postmolar	GTN	requiring	chemotherapy.
Prophylactic	administration	of	either	methotrexate	or	actinomycin	
D	chemotherapy	at	the	time	of	or	immediately	following	molar	evac-
uation	 is	 associated	with	 a	 reduction	 in	 the	 incidence	 of	 postmolar	
GTN	to	3%–8%.	However,	it	should	be	limited	to	special	situations	in	
which	the	risk	of	postmolar	GTN	is	much	greater	than	normal	or	where	
adequate	hCG	follow-	up	is	not	possible.13
Box 1 FIGO criteria for diagnosis of postmolar gesta-
tional trophoblastic neoplasia.
•	 When	the	plateau	of	hCG	lasts	for	four	measurements	over	a	
period	of	3	weeks	or	longer;	that	is,	days	1,	7,	14,	21.
•	 When	 there	 is	 a	 rise	 in	 hCG	 for	 three	 consecutive	weekly	
measurements	 over	 at	 least	 a	 period	 of	 2	weeks	 or	more;	
days	1,	7,	14.
•	 If	there	is	a	histologic	diagnosis	of	choriocarcinoma.
Abbreviation:	hCG,	human	chorionic	gonadotropin.
Box 2 Tools for investigation of gestational tropho-
blastic neoplasia.
•	 Chest	X-ray	is	appropriate	to	diagnose	lung	metastases	and	
can	be	used	for	counting	the	number	of	lung	metastases	to	
evaluate	the	risk	score.	Lung	CT	may	be	used.
•	 Liver	 metastases	 may	 be	 diagnosed	 by	 ultrasound	 or	 CT	
scanning.
•	 Brain	metastases	may	be	diagnosed	by	MRI	or	CT	scanning.
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Follow-	up	 hCG	 monitoring	 every	 1–2	weeks	 is	 essential	 for	
early	 diagnosis	 of	 and	 management	 of	 postmolar	 GTN.	 On	 the	
other	 hand,	 postmolar	 GTN	 rarely	 occurs	 after	 the	 spontaneous	
return	of	hCG	levels	to	normal,	allowing	for	a	shortened	follow-	up	
period	 for	most	women.	Hence,	 a	 single	 additional	 confirmatory	
normal	hCG	measurement	1	month	after	 first	hCG	normalization	
is	 recommended	 for	 a	 PHM	 and	 monthly	 hCG	 measurements	
should	be	obtained	for	only	6	months	after	hCG	normalization	for	
a	CHM.2,14	Termination	of	pregnancy	 is	 not	 indicated	 if	 acciden-
tal	 pregnancy	occurs	 during	 surveillance	 after	 the	 hCG	 level	 has	
returned	 to	normal.	 In	addition,	data	now	show	that	 it	 is	 safe	 to	
recommend	oral	contraceptives.15
The	risk	of	recurrence	is	low	(0.6%–2%)	after	one	molar	pregnancy,	
although	 much	 increased	 after	 consecutive	 molar	 pregnancies.16 
Mutations	in	NLRP7	and	KHDC3L	have	been	reported	in	women	with	
recurrent	molar	pregnancy.5,6
5.2 | Coexisting normal pregnancy with mole
Molar	pregnancy	rarely	coexists	with	a	normal	pregnancy.	The	diag-
nosis	 is	usually	made	on	ultrasound.	Although	there	is	a	high	risk	of	
spontaneous	abortion,	about	40%–60%	result	in	live	births.	The	risk	
of	 GTN	 in	 coexisting	 molar	 and	 normal	 pregnancy	 compared	 with	
singleton	molar	pregnancy	is	increased	from	15%	to	20%	to	27%	to	
46%.17,18	 In	 the	 absence	 of	 complications	 and	 normal	 genetic	 and	
ultrasound	findings,	pregnancy	can	proceed.
5.3 | Gestational trophoblastic neoplasia
Treatment	of	GTN	 is	generally	by	chemotherapy.	The	best	 regimen	
depends	 on	 stage	 and	 classification.	 In	 the	 2000	FIGO	 staging	 and	
classification	(Tables	1	and	2),	a	risk	score	of	6	and	below	is	classified	
as	low	risk	and	above	6	is	considered	high	risk.
5.3.1 | Low- risk gestational trophoblastic neoplasia
Patients	with	low-	risk	GTN	(WHO	risk	score	0–4)	should	be	treated	
with	one	of	the	single	agent	methotrexate	or	actinomycin	D	protocols	
listed	in	Box	3.	The	Cochrane	Review	in	2012,	including	513	patients	
in	five	randomized	controlled	trials,	showed	that	actinomycin	D	(Act-	
D)	 appeared	 to	 be	 superior	 to	methotrexate	 (MTX)	 (risk	 ratio	 [RR]	
0.64;	95%	confidence	 interval,	 [CI]	0.54–0.76).19	Methotrexate	was	
associated	with	significantly	more	treatment	failure	than	actinomycin	
D	(RR	3.81;	95%	CI	1.64–8.86).
Chemotherapy	 should	 be	 changed	 to	 the	 alternative	 single	 agent	 if	
there	has	been	a	good	response	 to	 the	first	agent	but	 the	hCG	 level	
plateaus	above	normal	during	treatment,	or	if	toxicity	precludes	an	ade-
quate	dose	or	frequency	of	treatment.	If	there	is	an	inadequate	response	
T A B L E  1  FIGO	staging	and	classification	for	gestational	
trophoblastic	neoplasia.
FIGO Stage Description
I Gestational	trophoblastic	tumors	strictly	confined	to	
the	uterine	corpus
II Gestational	trophoblastic	tumors	extending	to	the	
adnexae	or	to	the	vagina,	but	limited	to	the	genital	
structures
III Gestational	trophoblastic	tumors	extending	to	the	
lungs,	with	or	without	genital	tract	involvement
IV All	other	metastatic	sites
T A B L E  2  WHO	scoring	system	based	on	prognostic	factors.
WHO risk factor scoring with FIGO staging 0 1 2 4
Age <40 >40 — —
Antecedent	pregnancy Mole Abortion Term
Interval	from	index	pregnancy,	months <4 4–6 7–12 >12
Pretreatment	hCG	mIU/mL <103 >103–104 >104–105 >105
Largest	tumor	size	including	uterus,	cm — 3–4 ≥5 —
Site	of	metastases	including	uterus Lung Spleen,	kidney Gastrointestinal	tract Brain,	liver
Number	of	metastases	identified — 1–4 5–8 >8
Previous	failed	chemotherapy — — Single	drug Two	or	more	drugs
To	stage	and	allot	a	risk	factor	score,	a	patient’s	diagnosis	is	allocated	to	a	Stage	as	represented	by	a	Roman	numeral	I,	II,	III,	or	IV.	This	is	then	separated	
by	a	colon	from	the	sum	of	all	the	actual	risk	factor	scores	expressed	in	Arabic	numerals	e.g.	Stage	II:4,	Stage	IV:9.	This	Stage	and	score	will	be	allotted	for	
each	patient.
Box 3 First- line single agent chemotherapy regimens for 
low- risk gestational trophoblastic neoplasia.
•	 MTX-FA	8-day	regimen	(50	mg	MTX	intramuscularly	on	days	
1,3,5,7	with	folinic	acid	15	mg	orally	24	hours	after	MTX	on	
days	2,4,6,8);	repeat	every	2	weeks.
•	 MTX	0.4	mg/kg	(max.	25	mg)	intravenously	or	intramuscularly	
for	5	days	every	2	weeks.
•	 Actinomycin	 D	 pulse	 1.25	mg/m2	 intravenously	 every	
2	weeks.
•	 Actinomycin	D	0.5	mg	intravenously	for	5	days	every	2	weeks
•	 Others:	 MTX	 30–50	mg/m2	 intramuscularly	 weekly,	 MTX	
300 mg/m2	infusion	every	2	weeks
Abbreviations:	MTX-	FA,	methotrexate–folinic	acid.
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to	the	initial	single	agent,	multiple	agent	chemotherapy	as	for	high-	risk	
disease	should	be	initiated	if	there	is	a	significant	elevation	in	hCG	level,	
development	of	metastasis,	or	resistance	to	sequential	single	agent	che-
motherapy.3	Studies	showed	that	change	to	single	agent	Act-	D	gives	a	
good	response	rate	of	between	76%	and	87%	in	patients	with	relatively	
low	hCG	levels3,20;	as	there	are	continuous	updates	on	the	cutoff	level	
based	on	evolving	data,	physicians	should	refer	to	local	guidelines	from	
time	to	time.	Otherwise,	multiple	agents	should	be	considered.
Higher	WHO	 risk	 score	 (5–6)	 and	 clinicopathologic	 diagnosis	 of	
choriocarcinoma	are	both	associated	with	an	 increased	risk	of	resis-
tance	to	single	agent	chemotherapy.	Lowering	the	threshold	 for	 the	
use	 of	 multiple	 agent	 chemotherapy	 in	 these	 otherwise	 low-	risk	
patients	can	be	considered.
After	the	hCG	level	has	returned	to	normal,	consolidation	with	2–3	
more	cycles	of	chemotherapy	will	decrease	the	chance	of	recurrence.	
The	overall	complete	remission	rate	is	close	to	100%.3,21
5.3.2 | High- risk gestational trophoblastic neoplasia
Multiple	 agent	 chemotherapy	 regimens	 are	 used	 to	 treat	 high-	risk	
GTN.	The	most	commonly	used	is	EMA-	CO	(etoposide,	methotrexate,	
actinomycin	D,	cyclophosphamide,	vincristine)	(Table	3),	although	the	
Cochrane	Database	review	failed	to	conclude	what	combination	was	
best.22	About	20%	of	patients	fail	EMA-	CO	therapy	but	most	can	be	
salvaged	with	further	therapy;	the	overall	survival	rates	for	patients	
with	 high-	risk	GTN	 are	 now	 running	 as	 high	 as	 95%.	 A	 number	 of	
adverse	features	that	predict	poorer	outcomes,	including	liver	and/or	
brain	metastasis23,24	and	the	management	of	such	patients	together	
with	salvage	therapies	are	discussed	below.
5.3.3 | Ultra high- risk gestational trophoblastic 
neoplasia and salvage therapy
Among	the	high-	risk	group	as	defined	by	the	FIGO	staging	and	clas-
sification,	a	subgroup	with	score	of	13	or	greater,	as	well	as	patients	
with	liver,	brain,	or	extensive	metastases,	do	poorly	when	treated	with	
first-	line	 multiple	 agent	 chemotherapy.	 Similar	 findings	 have	 been	
reported	by	others.25
For	 those	with	massive	disease,	 starting	with	 standard	chemo-
therapy	may	cause	sudden	tumor	collapse	with	severe	bleeding,	met-
abolic	 acidosis,	 myelosuppression,	 septicemia,	 and	 multiple	 organ	
failure,	 any	or	 all	 of	which	 can	 result	 in	 early	death.	To	avoid	 this,	
the	use	of	 initial	gentle	 rather	 than	 full-	dose	chemotherapy	seems	
logical.	Indeed,	induction	etoposide	100	mg/m2	and	cisplatin	20	mg/
m2	on	days	1	and	2,	repeated	weekly	for	1–3	weeks,	before	starting	
normal	 chemotherapy	 appears	 to	 have	 eliminated	 early	 deaths	 in	
one series26	with	promising	results	now	reported	by	others.25
For	 those	 patients	with	 liver	 metastases,	 with	 or	 without	 brain	
metastases,	 or	 a	 very	 high-	risk	 score,	 EP	 (etoposide	 and	 platinum)/
EMA	or	another	more	intensive	chemotherapy	regimen	(Box	4),	rather	
than	EMA-	CO,	may	yield	a	better	response	and	outcome.23	For	such	
high-	risk	patients,	a	 longer	consolidation	with	four	cycles	of	chemo-
therapy	should	be	considered.
In	patients	with	brain	metastases,	an	increase	in	the	methotrexate	
infusion	to	1	g/m2	will	help	the	drug	cross	the	blood–brain	barrier	and	
intrathecal	methotrexate	12.5	mg	may	be	used	in	some	centers.	This	
can	be	given	at	the	time	of	CO	when	EMA-	CO	is	used,	or	with	the	EP	
in	 the	EP/EMA	 regimen.	 Some	centers	may	give	whole	brain	 radio-
therapy	3000	cGy	in	200	cGy	daily	fractions	concurrent	with	chemo-
therapy	or	use	stereotactic	or	gamma	knife	radiation	to	treat	existing	
or	 residual	 brain	 metastases	 after	 chemotherapy.27	 Patients	 failing	
EMA-	CO	are	mostly	salvaged	with	paclitaxel	and	etoposide	alternat-
ing	with	 paclitaxel	 and	 cisplatin	 (TE/TP)	 or	with	 EP/EMA.	 In	China,	
the	5FU-	based	FAEV	regimen	is	also	an	effective	salvage	treatment.	
For	women	 failing	 EP/EMA	 or	 TE/TP,	 options	 include	 a	 number	 of	
other	standard	or	high-	dose	chemotherapy	regimens	with	autologous	
T A B L E  3  EMA-	CO	(etoposide,	methotrexate,	actinomycin	D,	
cyclophosphamide,	vincristine)	chemotherapy.
Regimens
Regimen	1
Day 1
Etoposide 100 mg/m2	intravenous	infusion	over	
30 min
Actinomycin-	D 0.5	mg	intravenous	bolus
Methotrexate 100 mg/m2	intravenous	bolus
200 mg/m2	intravenous	infusion	over	12	h
Day 2
Etoposide 100 mg/m2	intravenous	infusion	over	30	min
Actinomycin-	D 0.5	mg	intravenous	bolus
Folinic	acid	rescue 15	mg	intramuscularly	or	orally	every	12	h	
for	four	doses	(starting	24	h	after	
beginning	the	methotrexate	infusion)
Regimen	2
Day 8
Vincristine 1 mg/m2	intravenous	bolus	(maximum	2	mg)
Cyclophosphamide 600 mg/m2	intravenous	infusion	over	30	min
The	two	regimens	alternate	each	week
Box 4 Salvage therapies.
•	 EP-EMA	 (etoposide,	 cisplatin,	 etoposide,	 methotrexate	 and	
actinomycin-D)
•	 TP/TE	(paclitaxel,	cisplatin/paclitaxel,	etoposide)
•	 MBE	(methotrexate,	bleomycin,	etoposide)
•	 VIP	 or	 ICE	 (etoposide,	 ifosfamide,	 and	 cisplatin	 or	
carboplatin)
•	 BEP	(bleomycin,	etoposide,	cisplatin)
•	 FA	(5-fluorouracil,	actinomycin-D)
•	 FAEV	(floxuridine,	actinomycin-D,	etoposide,	vincristine)
•	 High-dose	 chemotherapy	 with	 autologous	 bone	 marrow	 or	
stem	cell	transplant
•	 Immunotherapy	with	pembrolizumab
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peripheral	stem	cell	support	(Box	4).	Recent	work	suggests	that	check-
point	 immunotherapies	such	as	pembrolizumab	may	also	save	some	
women.28	Finally,	surgical	salvage	should	not	be	overlooked.
5.4 | Role of surgery
Surgery	 may	 have	 an	 important	 role	 in	 the	 management	 of	 GTN.	
Hysterectomy	 can	 be	 considered	 in	 uncontrolled	 uterine	 bleeding,	
although	it	can	often	be	avoided	with	the	use	of	uterine	artery	embo-
lization.	Laparotomy	may	be	needed	to	stop	bleeding	in	organs	such	
as	the	liver,	gastrointestinal	tract,	kidneys,	and	spleen.	Neurosurgery	
is	needed	if	there	is	bleeding	into	the	brain	or	increased	intracranial	
pressure.	The	resection	of	an	isolated	drug-	resistant	tumor	may	also	
be	curative.4,11
5.5 | Role of radiotherapy
Radiotherapy	has	a	limited	role	in	GTN,	except	in	treatment	of	brain	
metastasis,	 although	 its	 efficacy	 compared	 with	 intrathecal	 metho-
trexate	is	controversial.4,11
5.6 | PSTT/ETT
Both	PSTT	and	ETT	are	less	chemosensitive	than	choriocarcinoma.	
Hysterectomy	is	the	primary	mode	of	treatment	in	most	cases	and	
surgery	also	plays	an	 important	 role	 in	metastatic	disease.	 If	 fer-
tility	preservation	 is	desired,	especially	 in	a	 localized	 lesion,	 con-
servative	 management	 such	 as	 uterine	 curettage,	 hysteroscopic	
resection,	and	chemotherapy	may	be	considered.29	Fertility	preser-
vation	is	not	suitable	in	diffuse	lesions.	In	advanced	stage,	EP-	EMA	
or	TE/TP	can	be	considered.	 Interval	 from	antecedent	pregnancy	
of	more	than	48	months	seems	to	be	the	most	significant	adverse	
prognostic	factor.30
5.7 | Follow- up
After	treatment	of	GTN,	follow-	up	hCG	monitoring	every	month	for	at	
least	12	months	is	essential	for	surveillance	of	relapse.	Reliable	con-
traception	must	be	used	throughout	this	period.
Future	fertility,	pregnancy,	and	offspring	are	not	affected,	although	
psychosocial	and	sexual	counseling	may	be	needed	for	some	patients.
6  | ESTABLISHMENT OF A (NATIONAL) 
GTD CENTER
Centralized	care	is	needed	for	optimal	management	of	a	rare	disease	
like	 GTD.	Without	 some	 type	 of	 centralization,	 treatment	 decisions	
will	 be	 inconsistent.	 Centralized	 management	 can	 vary	 from	 only	
hCG	monitoring	 with	 treatment	 advice	 to	 patient	 referral.	 Creating	
a	 center	 is	 not	 easy.	 It	 starts	with	 sharing	 the	 idea	with	 colleagues	
and	promoting	 it	 at	national	meetings.	Make	sure	you	have	support	
from	the	national	obstetrics	and	gynecology	governing	body.	Create	a	
multidisciplinary	team	of	gynecology,	gynecological	oncology,	medical	
oncology,	pathology,	and	the	hCG	laboratory.	Work	with	a	clear	model	
of	care.	Create	a	clinical	guidelines	committee,	create	a	database,	and	
develop	a	website.	Some	 form	of	annual	 funding	will	be	needed	 for	
the	center	to	develop	and	maintain	a	database,	website,	patient	infor-
mation,	reading	material,	and	nursing	staff,	and	to	allow	presentations	
at	national	meetings.	Try	to	establish	central	pathology	review	for	the	
whole region.
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